Lifetime changes in body fatness and breast density in postmenopausal women: the FEDRA study.
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
31 03 2023
31 03 2023
Historique:
received:
03
08
2022
accepted:
27
02
2023
medline:
4
4
2023
entrez:
2
4
2023
pubmed:
3
4
2023
Statut:
epublish
Résumé
High mammographic breast density (MBD) is an established risk factor for breast cancer (BC). Body fatness conveys an increased BC risk in postmenopause but is associated with less dense breasts. Here, we studied the relationship between body fatness and breast composition within the FEDRA (Florence-EPIC Digital mammographic density and breast cancer Risk Assessment) longitudinal study. Repeated anthropometric data and MBD parameters (obtained through an automated software on BC screening digital mammograms) were available for all participants, as well as information on other BC risk factors. Multivariate linear regression and functional data analysis were used to longitudinally evaluate the association of body fatness, and changes thereof over time, with dense (DV) and non-dense (NDV) breast volumes and volumetric percent density (VPD). A total of 5,262 women were included, with anthropometric data available at 20 and 40 years of age, at EPIC baseline (mean 49.0 years), and an average of 9.4 years thereafter. The mean number of mammograms per woman was 3.3 (SD 1.6). Body fatness (and increases thereof) at any age was positively associated with DV and NDV (the association being consistently stronger for the latter), and inversely associated with VPD. For instance, an increase by 1 kg/year between the age of 40 years and EPIC baseline was significantly associated with 1.97% higher DV, 8.85% higher NDV, and 5.82% lower VPD. Body fatness and its increase from young adulthood until midlife are inversely associated with volumetric percent density, but positively associated with dense and non-dense breast volumes in postmenopausal women.
Sections du résumé
BACKGROUND
High mammographic breast density (MBD) is an established risk factor for breast cancer (BC). Body fatness conveys an increased BC risk in postmenopause but is associated with less dense breasts. Here, we studied the relationship between body fatness and breast composition within the FEDRA (Florence-EPIC Digital mammographic density and breast cancer Risk Assessment) longitudinal study.
METHODS
Repeated anthropometric data and MBD parameters (obtained through an automated software on BC screening digital mammograms) were available for all participants, as well as information on other BC risk factors. Multivariate linear regression and functional data analysis were used to longitudinally evaluate the association of body fatness, and changes thereof over time, with dense (DV) and non-dense (NDV) breast volumes and volumetric percent density (VPD).
RESULTS
A total of 5,262 women were included, with anthropometric data available at 20 and 40 years of age, at EPIC baseline (mean 49.0 years), and an average of 9.4 years thereafter. The mean number of mammograms per woman was 3.3 (SD 1.6). Body fatness (and increases thereof) at any age was positively associated with DV and NDV (the association being consistently stronger for the latter), and inversely associated with VPD. For instance, an increase by 1 kg/year between the age of 40 years and EPIC baseline was significantly associated with 1.97% higher DV, 8.85% higher NDV, and 5.82% lower VPD.
CONCLUSION
Body fatness and its increase from young adulthood until midlife are inversely associated with volumetric percent density, but positively associated with dense and non-dense breast volumes in postmenopausal women.
Identifiants
pubmed: 37004102
doi: 10.1186/s13058-023-01624-5
pii: 10.1186/s13058-023-01624-5
pmc: PMC10067176
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
35Informations de copyright
© 2023. The Author(s).
Références
Lancet. 2019 Sep 28;394(10204):1159-1168
pubmed: 31474332
J Clin Oncol. 2013 Jun 20;31(18):2249-56
pubmed: 23610119
Breast Cancer Res Treat. 2017 Nov;166(1):197-206
pubmed: 28702890
Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):3096-105
pubmed: 20921336
Breast Cancer Res. 2014 Sep 20;16(5):439
pubmed: 25239205
Cancer Prev Res (Phila). 2020 May;13(5):475-482
pubmed: 32102947
J Natl Cancer Inst. 2015 Feb 06;107(3):
pubmed: 25663687
Br J Cancer. 2005 Sep 5;93(5):582-9
pubmed: 16136032
Breast Cancer Res Treat. 2017 Jul;164(2):467-473
pubmed: 28478611
Breast Cancer Res Treat. 2019 Aug;177(1):165-173
pubmed: 31129803
Tumori. 2003 Nov-Dec;89(6):586-93
pubmed: 14870823
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Breast Cancer Res. 2012 Nov 15;14(6):R147
pubmed: 23152984
Obes Rev. 2005 May;6(2):175-6
pubmed: 15836468
J Natl Cancer Inst. 2011 May 4;103(9):744-52
pubmed: 21483019
Arch Intern Med. 2007 Oct 22;167(19):2091-102
pubmed: 17954804
Int J Cancer. 2016 May 15;138(10):2346-56
pubmed: 26684063
Int J Mol Sci. 2020 Aug 11;21(16):
pubmed: 32796696
Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2086-92
pubmed: 17119032
Jpn J Clin Oncol. 2020 Dec 16;50(12):1481-1482
pubmed: 33205816
Br J Cancer. 2002 Oct 7;87(8):876-82
pubmed: 12373602
Eur J Cancer Prev. 2017 Nov;26(6):511-520
pubmed: 27571214
PLoS One. 2014 Jan 21;9(1):e85952
pubmed: 24465808
J Natl Cancer Inst. 2014 May 10;106(5):
pubmed: 24816206
Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1159-69
pubmed: 16775176
Int J Cancer. 2014 Dec 15;135(12):2887-99
pubmed: 24771551
Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9):1450-1458
pubmed: 28698185
Breast Cancer Res. 2012 Jul 06;14(4):R102
pubmed: 22770227
Br J Cancer. 1998 Nov;78(9):1233-8
pubmed: 9820186